Hepatitis C Infection Clinical Trial
Official title:
Response Guided Therapy (RGT) for Boceprevir Combined With Peginterferon Alpha-2b Plus Ribavirin in Naïve Hispanic Patients With Genotype 1 Hepatitis C Infection
Hypothesis Response guided therapy improves significantly the overall SVR in Hispanics compared to historical control. There is no difference in SVR between patients with an undetectable HCV RNA at week 8 and week 28 who received a 4 week lead-in of PR plus 24 weeks of PR+BOC based treatment and patients with detectable HCV RNA at week 8 and undetectable HCV RNA at week 24 who received a lead-in of PR plus 32 weeks PR+BOC followed by based therapy and 12 weeks of PR.
STUDY DESIGN AND ENROLLMENT Open label single arm pilot study enrolling Hispanic patients
with HCV genotype 1 and naive to pegylated interferon and BOC treatment.
Definition of BOC RGT:
All patients will receive 4 weeks of PR (lead-in), and BOC will be added at the beginning of
week 5. Patients who have an undetectable HCV RNA at week 8 and week 24 will receive 24 weeks
of PR and BOC (28 weeks total treatment); patients who have a detectable HCV RNA at week 8,
but an undetectable HCV RNA at week 24, will receive an additional 32 weeks of PR and BOC,
followed by 12 weeks of PR (48 weeks total treatment).
Patients with cirrhosis or bridging fibrosis (Stage 4 fibrosis) will receive 4 weeks of lead
in followed by 44 weeks of BOC and PR (total 48 weeks).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01771653 -
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
|
N/A | |
Recruiting |
NCT03601546 -
Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
|
||
Completed |
NCT02362217 -
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
|
Phase 1 | |
Completed |
NCT00513461 -
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
|
Phase 2 | |
Active, not recruiting |
NCT02143401 -
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
Completed |
NCT02582632 -
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
|
Phase 3 | |
Terminated |
NCT01532908 -
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
|
Phase 2 | |
Recruiting |
NCT01754961 -
Effects of Vitamin D on Inflammation in Liver Disease
|
Phase 2 | |
Completed |
NCT01265511 -
Study of SCY-635, Pegasys and Copegus in Hepatitis C
|
Phase 2 | |
Completed |
NCT04042740 -
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
|
Phase 2 | |
Not yet recruiting |
NCT05601518 -
Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
|
||
Terminated |
NCT02429583 -
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
|
Phase 4 | |
Not yet recruiting |
NCT05506475 -
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
|
||
Terminated |
NCT01841502 -
Interaction Between Paroxetine and Telaprevir
|
Phase 2 | |
Withdrawn |
NCT02112630 -
Boceprevir in End Stage Renal Disease (ESRD)
|
N/A | |
Completed |
NCT02076100 -
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
|
Phase 1 | |
Completed |
NCT01803308 -
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
|
Phase 1 | |
Terminated |
NCT01560468 -
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
|
Phase 1 | |
Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 |